Using blood samples from 200 cancer patients, researchers showed that it is possible to find most early cancer cases with targeted error correction sequencing.
In a retrospective cohort study of Lynch syndrome patients, researchers found that cancer onset varied both by which gene was mutated and how it was altered.
The Stanford University and Fox Chase Cancer Center team found that some mutations dramatically increased cancer risk, while others had a more modest effect.
The organization named the institutions that will be performing the proteomic and proteogenomic analyses planned to for the five-year, $65 million effort.
The company plans to submit a package to the FDA by the end of this year for use of the system in metastatic breast cancer patients, and then add other cancer types in the future.
The study will use OncoDNA's liquid biopsy tech to profile and identify treatment options for 100 patients in Lebanon, Jordan, Saudi Arabia, and the UAE.
